Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

This is a two-part Phase 2a study compromising a 12-week, double-blind, placebo-controlled,
treatment period followed by a 100-week, open label, treatment period to evaluate short-term
efficacy, and the short- and long-term safety of MEDI2070 in subjects with moderate to
severe, active CD who have failed or are intolerant to anti-TNFα therapy as determined by the
investigator. Approximately 120 subjects will be randomized in a 1:1 ratio to initially
receive a fixed IV dose of MEDI2070 or placebo on Week 0(Day1) and Week 4 (Day 29) during the
12-week, double-blind, placebo-controlled, treatment period. At the completion of the
double-blind, placebo-controlled, treatment period (Week 12), subjects will have the option
to enter a 100-week, open-label, treatment period where they will receive open-label MEDI2070
(SC) Q4W (Week 12 through Week 112). Subjects will be followed for safety at 3 visits over 28
weeks after their last dose of IP. Subjects will also be contacted by phone 36 weeks after
their last dose of IP for safety.

Inclusion Criteria:

- Diagnosed ileal, ileo-colonic, or colonic CD at least 6 months prior to screening.

- Men or women age 18 - 65 years at the time of screening.

- Moderate-sever active Crohn's Disease (CD), defined by a Crohn's Disease Activity
Index (CDAI) score higher or equal 220 and lower or equal 450 at Day 1.

- No known history of active tuberculosis (TB).

- Received at least one anti-TNFα agent for the treatment of CD and did not initially
respond.

Exclusion Criteria:

- Pregnant or breastfeeding women.

- Presence of ileostomy and/or colostomy.

- Short bowel syndrome.

- Bowel perforation or obstruction.

- History of cancer.